The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
MAFLD: How is it different from NAFLD?
Open accessAbstract
“Metabolic dysfunction-associated fatty liver disease (MAFLD)” is the term suggested in 2020 to refer to fatty liver disease related to systemic metabolic dysregulation. The name change from nonalcoholic fatty liver disease (NAFLD) to MAFLD comes with a simple set of criteria to enable easy diagnosis at the bedside for the general medical community, including primary care physicians. Since the introduction of the term, there have been key areas in which the superiority of MAFLD over the traditional NAFLD terminology has been demonstrated, including for the risk of liver and extrahepatic mortality, disease associations, and for identifying high-risk individuals. Additionally, MAFLD has been adopted by a number of leading pan-national and national societies due to its concise diagnostic criterion, removal of the requirement to exclude concomitant liver diseases, and reduction in the stigma associated with this condition. The current article explores the differences between MAFLD and NAFLD diagnosis, areas of benefit, some potential limitations, and how the MAFLD terminology has opened up new fields of research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Self-citationLudwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
EASL Clinical Practice Guidelines: Management of alcohol-related liver disease
Thursz, M., Gual, A., Lackner, C., Mathurin, P., Moreno, C., Spahr, L., Sterneck, M., & Cortez-Pinto, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.018 · Cited by 943
Why does obesity cause diabetes?
Klein, S., Gastaldelli, A., Yki-Järvinen, H., & Scherer, P. E. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.012 · Cited by 939
Eslam, M., Sarin, S. K., Wong, V. W.-S., Fan, J.-G., Kawaguchi, T., Ahn, S. H., Zheng, M.-H., Shiha, G., Yilmaz, Y., Gani, R., et al. (2020) · Hepatology International · doi:10.1007/s12072-020-10094-2 · Cited by 833
Self-citationAdvancing the global public health agenda for NAFLD: a consensus statement
Lazarus, J. V., Mark, H. E., Anstee, Q. M., Arab, J. P., Batterham, R. L., Castera, L., Cortez-Pinto, H., Crespo, J., Cusi, K., Dirac, M. A., et al. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00523-4 · Cited by 757
Self-citationThe epidemiology of non‐alcoholic fatty liver disease
Bellentani, S. (2017) · Liver International · doi:10.1111/liv.13299 · Cited by 606
Targher, G., Tilg, H., & Byrne, C. D. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00020-0 · Cited by 586
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease
European Association for the Study of the Liver (EASL), E. A. F. T. S. O. D. (. (2016) · Obesity Facts · doi:10.1159/000443344 · Cited by 521
Comparison of MAFLD and NAFLD diagnostic criteria in real world
Lin, S., Huang, J., Wang, M., Kumar, R., Liu, Y., Liu, S., Wu, Y., Wang, X., & Zhu, Y. (2020) · Liver International · doi:10.1111/liv.14548 · Cited by 516
Lee, H., Lee, Y.-H., Kim, S. U., & Kim, H. C. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.12.022 · Cited by 463
MAFLD identifies patients with significant hepatic fibrosis better than NAFLD
Yamamura, S., Eslam, M., Kawaguchi, T., Tsutsumi, T., Nakano, D., Yoshinaga, S., Takahashi, H., Anzai, K., George, J., & Torimura, T. (2020) · Liver International · doi:10.1111/liv.14675 · Cited by 401
From NAFLD in clinical practice to answers from guidelines
Nascimbeni, F., Pais, R., Bellentani, S., Day, C. P., Ratziu, V., Loria, P., & Lonardo, A. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.05.044 · Cited by 337
Barriers to alcoholism treatment: reasons for not seeking treatment in a general population sample.
Grant, B. F. (1997) · Journal of Studies on Alcohol · doi:10.15288/jsa.1997.58.365 · Cited by 334
Sun, D.-Q., Jin, Y., Wang, T.-Y., Zheng, K. I., Rios, R. S., Zhang, H.-Y., Targher, G., Byrne, C. D., Yuan, W.-J., & Zheng, M.-H. (2021) · Metabolism · doi:10.1016/j.metabol.2020.154433 · Cited by 308
Self-citationCurrent treatment of non‐alcoholic fatty liver disease
Paternostro, R., & Trauner, M. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13531 · Cited by 305
Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease
Alexander, M., Loomis, A. K., Fairburn-Beech, J., van der Lei, J., Duarte-Salles, T., Prieto-Alhambra, D., Ansell, D., Pasqua, A., Lapi, F., Rijnbeek, P., et al. (2018) · BMC Medicine · doi:10.1186/s12916-018-1103-x · Cited by 272
Lim, G. E. H., Tang, A., Ng, C. H., Chin, Y. H., Lim, W. H., Tan, D. J. H., Yong, J. N., Xiao, J., Lee, C. W.-M., Chan, M., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.11.038 · Cited by 246
Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD
Nguyen, V. H., Le, M. H., Cheung, R. C., & Nguyen, M. H. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.05.029 · Cited by 216
Microbiome-derived ethanol in nonalcoholic fatty liver disease
Meijnikman, A. S., Davids, M., Herrema, H., Aydin, O., Tremaroli, V., Rios-Morales, M., Levels, H., Bruin, S., de Brauw, M., Verheij, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02016-6 · Cited by 215
Staufer, K., Huber-Schönauer, U., Strebinger, G., Pimingstorfer, P., Suesse, S., Scherzer, T.-M., Paulweber, B., Ferenci, P., Stimpfl, T., Yegles, M., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.040 · Cited by 190
Redefining fatty liver disease: an international patient perspective
Shiha, G., Korenjak, M., Eskridge, W., Casanovas, T., Velez-Moller, P., Högström, S., Richardson, B., Munoz, C., Sigurðardóttir, S., Coulibaly, A., et al. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30294-6 · Cited by 189
Are there outcome differences between NAFLD and metabolic‐associated fatty liver disease?
Younossi, Z. M., Paik, J. M., Al Shabeeb, R., Golabi, P., Younossi, I., & Henry, L. (2022) · Hepatology · doi:10.1002/hep.32499 · Cited by 182
Méndez‐Sánchez, N., Arrese, M. A., Gadano, A. C., de Oliveira, C. P. M. S., Fassio, E., Arab, J. P., Chávez-Tapia, N. C., Dirchwolf, M., Torre, A., Ridruejo, E., et al. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(20)30340-x · Cited by 149
MAFLD: Renovation of clinical practice and disease awareness of fatty liver
Kawaguchi, T., Tsutsumi, T., Nakano, D., & Torimura, T. (2021) · Hepatology Research · doi:10.1111/hepr.13706 · Cited by 133
Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD
Rinella, M. E., Tacke, F., Sanyal, A. J., Anstee, Q. M., & Workshop, O. B. O. T. P. O. T. A. (2019) · Hepatology · doi:10.1002/hep.30782 · Cited by 127
Huang, Q., Zou, X., Wen, X., Zhou, X., & Ji, L. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.693507 · Cited by 123
The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease
Nan, Y., An, J., Bao, J., Chen, H., Chen, Y., Ding, H., Dou, X., Duan, Z., Fan, J., Gao, Y., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.003 · Cited by 121
Tang, A. S. P., Ng, C. H., Phang, P. H., Chan, K. E., Chin, Y. H., Fu, C. E., Zeng, R. W., Xiao, J., Tan, D. J. H., Quek, J., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.06.029 · Cited by 120
Ayada, I., van Kleef, L. A., Alferink, L. J. M., Li, P., de Knegt, R. J., & Pan, Q. (2021) · Liver International · doi:10.1111/liv.15139 · Cited by 110
Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study
Niriella, M. A., Ediriweera, D. S., Kasturiratne, A., Silva, S. D., Dassanayaka, A. S., Silva, A. P. D., Kato, N., Pathmeswaran, A., Wickramasinghe, A. R., & de Silva, H. J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0245762 · Cited by 104
Kang, S. H., Cho, Y., Jeong, S. W., Kim, S. U., Lee, J., & On behalf of Korean NAFLD Study Group (2021) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2021.0067 · Cited by 102
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
Kawaguchi, T., Tsutsumi, T., Nakano, D., Eslam, M., George, J., & Torimura, T. (2021) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2021.0310 · Cited by 94
Self-citationAwareness and opinions of non‐alcoholic fatty liver disease by hospital specialists
Bergqvist, C. ‐., Skoien, R., Horsfall, L. U., Clouston, A. D., Jonsson, J. R., & Powell, E. E. (2012) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2012.02848.x · Cited by 89
Low Awareness of Nonalcoholic Fatty Liver Disease Among Patients at High Metabolic Risk
Wieland, A. C., Mettler, P., McDermott, M. T., Crane, L. A., Cicutto, L. C., & Bambha, K. M. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000075 · Cited by 85
Ng, C. H., Huang, D. Q., & Nguyen, M. H. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0070 · Cited by 82
Moon, J. H., Kim, W. K., Koo, B. K., & Cho, N. H. (2021) · Gut and Liver · doi:10.5009/gnl210167 · Cited by 79
Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?
Guerreiro, G. T. S., Longo, L., Fonseca, M. A., de Souza, V. E. G., & Álvares‐da‐Silva, M. R. (2021) · Hepatology International · doi:10.1007/s12072-021-10157-y · Cited by 65
Clinical utility of the MAFLD definition
Zheng, K. I., Sun, D., Jin, Y., Zhu, P., & Zheng, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.12.016 · Cited by 64
Self-citationCleveland, E. R., Ning, H., Vos, M. B., Lewis, C. E., Rinella, M. E., Carr, J. J., Lloyd‐Jones, D. M., & VanWagner, L. B. (2019) · Journal of General Internal Medicine · doi:10.1007/s11606-019-05340-9 · Cited by 60
Singh, A., Dhaliwal, A., Singh, S., Kumar, A., López, R., Gupta, M., Noureddin, M., Carey, W., McCullough, A. J., & Alkhouri, N. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05700-9 · Cited by 58
Zeng, J., Qin, L., Jin, Q., Yang, R., Ning, G., Su, Q., YANG, Z. K., & Fan, J. (2022) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2022.01.006 · Cited by 58
Muthiah, M. D., Ng, C. H., Chan, K. E., Fu, C. E., Lim, W. H., Tan, D. J. H., Nah, B. K. Y., Kong, G., Xiao, J., Yong, J. N., et al. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100762 · Cited by 54
Semmler, G., Wernly, S., Bachmayer, S., Leitner, I., Wernly, B., Egger, M., Schwenoha, L., Datz, L., Balcar, L., Semmler, M., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab339 · Cited by 48
Yu, C., Wang, M., Zheng, S., Xia, M., Yang, H., Zhang, D., Yin, C., Cheng, N., & Bai, Y. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00089 · Cited by 48
From NAFLD to MAFLD: Nurse and allied health perspective
Clayton, M., Fabrellas, N., Luo, J., Alghamdi, M., Hafez, A., Qadiri, T. A., Owise, N., & Attia, D. I. (2021) · Liver International · doi:10.1111/liv.14788 · Cited by 46
Bessho, R., Kashiwagi, K., Ikura, A., Yamataka, K., Inaishi, J., Takaishi, H., & Kanai∥, T. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269265 · Cited by 33
Miao, L., Yang, L., Guo, L., Shi, Q.-Q., Zhou, T.-F., Chen, Y., Zhang, H., Cai, H., Xu, Z., Yang, S., et al. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00306 · Cited by 30
Self-citationZhang, Y.-C., Lyu, Z., Ma, B., Li, L., Wang, W., Sheng, C., Dai, H., Huang, Y., Song, F.-F., Song, F., et al. (2022) · Hepatology International · doi:10.1007/s12072-022-10362-3 · Cited by 26
Kemp, W. W., Clayton‐Chubb, D., Majeed, A., Glenister, K., Magliano, D. J., Lubel, J. S., Bourke, L., Simmons, D. S., & Roberts, S. K. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15723 · Cited by 17
Fouad, Y., Palmer, M., Chen, M., Regev, A., Banerjee, R., Myers, R., Riccio, R., Torstenson, R., Younes, R., Arora, P. S., et al. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00408 · Cited by 17
Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study
Baratta, F., Ferro, D., Pastori, D., Colantoni, A., Cocomello, N., Coronati, M., Angelico, F., & Ben, M. D. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18178993 · Cited by 15
Fouad, Y. M., Palmer, M., Landgren, H., Karsdal, M. A., (10670712), M. B., (2393065), D. A. S., Gruss, H.-J., Sheikh, M. Y., Attia, D. I., Bollipo, S. J., et al. (2022) · Figshare · Cited by 14
Miyake, T., Matsuura, B., Furukawa, S., Ishihara, T., Yoshida, O., Miyazaki, M., Watanebe, K., Shiomi, A., Nakaguchi, H., Yamamoto, Y., et al. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13772 · Cited by 12
The NAFLD–MAFLD debate through the lens of the Arab world
Tharwat, M., Medhat, M. A., & El‐Kassas, M. (2022) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_314_22 · Cited by 7
Cited by
Metabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W. S., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki-Järvinen, H., & Loomba, R. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 293
ECM formation and degradation during fibrosis, repair, and regeneration
Mayorca-Guiliani, A. E., Leeming, D. J., Henriksen, K., Mortensen, J. H., Nielsen, S. H., Anstee, Q. M., Sanyal, A. J., Karsdal, M. A., & Schuppan, D. (2025) · npj Metabolic Health and Disease · doi:10.1038/s44324-025-00063-4 · Cited by 176
Guo, W., Li, Z., Anagnostopoulos, G., Kong, W. T., Zhang, S., Chakarov, S., Shin, A., Qian, J., Zhu, Y., Bai, W., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.08.016 · Cited by 109
Frankowski, R., Kobierecki, M., Wittczak, A., Różycka-Kosmalska, M., Pietras, T., Sipowicz, K., & Kosmalski, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119677 · Cited by 58
Yanagisawa, H., Maeda, H., Noguchi, I., Tanaka, M., Wada, N., Nagasaki, T., Kobayashi, K., Kanazawa, G., Taguchi, K., Chuang, V. T. G., et al. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103314 · Cited by 10
Metadata
- Authors
- Gofton, C., Upendran, Y., Zheng, M.-H., & George, J.
- Venue
- Clinical and Molecular Hepatology
- Published
- 2023-02-28
- Volume
- 29
- Issue
- Suppl
- Pages
- S17-S31
- ISSN
- 2287-2728 (ISSN-L)
- 2287-285X
- OpenAlex
- W4310463081
- Cited by
- 423
- References
- 56
- FWCI
- 53.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.